Cancer surgery: The last 25 years

Cancer Treatment Reviews

Volumn 25, Issue 6, 1999, Pages 333-353

  Bremers, A J A ^a   Rutgers, E J Th ^b   Van De Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Adjuvant treatment; Breast cancer; Colorectal cancer; Gastric carcinoma; History; Melanoma; Screening; Surgery; Surgical oncology; Surgical techniques

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; DOXORUBICIN; EDRECOLOMAB; FLUOROURACIL; GADOLINIUM; INTERFERON; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MITOMYCIN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SCREENING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DRUG TOXICITY; EARLY DIAGNOSIS; GASTRECTOMY; GENE MUTATION; GENE THERAPY; HIGH RISK POPULATION; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOMA; SURGICAL TECHNIQUE;

EID: 0033369073     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0147     Document Type: Article

References (212)

1. Hall J. C., Platell C. Half-life of truth in surgical literature. Lancet. 350:1997;1752.
2. Lancet. 353:1999;1373.
3. Cady B. Basic principles in surgical oncology. Archives of Surgery. 132:1997;338-346.
4. Liefers G. J., Cleton-Jansen A. M., van de Velde C. J. Micrometastases and survival in stage II colorectal cancer. New Eng J Med. 339:1998;223-228.
5. van den Akker-van Marle E., de Koning H., Boer R., van der Maas P. Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom. Journal of Medical Screening. 6:1999;30-34.
6. Sack H. [increasing incidence and declining mortality in breast carcinoma]. Strahlenther Onkol. 173:1997;388-389.
7. Newcomb P. A., Lantz P. M. Recent trends in breast cancer incidence, mortality, and mammography. Breast Cancer Res Treat. 28:1993;97-106.
8. Ursin G., Bernstein L., Pike M. C. Breast cancer. Cancer Surv. 19-20:1994;241-264.
9. Gastrin G., Miller A. B., To T. Incidence and mortality from breast cancer in the mama program for breast screening in finland, 1973-1986. Cancer. 73:1994;2168-2174.
10. Hanazaki K., Sodeyama H., Wakabayashi M. Surgical treatment of gastric cancer detected by mass screening. Hepatogastroenterology. 44:1997;1126-1132.
11. Robinson M. H., Hardcastle J. D. Should we be screening for colorectal cancer? British Medical Bulletin. 54:1998;807-821.
12. Bond J. H. Screening guidelines for colorectal cancer. American Journal of Medicine. 106:1999;7S-10S.
13. Anwar S., Hall C., Elder J. B. Screening for colorectal cancer: present, past and future. Eur J Surg Oncol. 24:1998;477-486.
14. Burchert A., Schmassmann A. [Evaluation of various screening and surveillance methods in colorectal carcinoma]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Me. 1998;999-1011.
15. Lennard-Jones J. E. Is colonoscopic cancer surveillance in ulcerative colitis essential for every patient? Eur J Cancer. 31A:1995;1178-1182.
16. Broome U., Lofberg R., Veress B., Eriksson L. S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 22:1995;1404-1408.
17. Rutgers E. J., van Slooten E. A., Kluck H. M. Follow-up after treatment of primary breast cancer. Br J Surg. 76:1989;187-190.
18. Stiggelbout A. M., de Haes J. C., Vree R. Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. Br J Cancer. 75:1997;914-920.
19. JAMA. 271:1994;1587-1592.
20. Vrouenraets B. C., Keus R. B., Nieweg O. E., Kroon B. B. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. Journal of Surgical Oncology. 65:1997;88-94.
21. Nooijen P. T., Eggermont A. M., Schalkwijk L., Henzen-Logmans S., de Waal R. M., Ruiter D. J. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res. 58:1998;4880-4887.
22. de Vries M. R., Rinkes I. H., van de Velde C. J. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Rec Res Cancer Res. 147:1998;107-119.
23. Vahrmeijer A. L., van der Eb M. M., Van Dierendonck J. H., Kuppen P. J., van de Velde C. J. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Sem Surg Oncol. 14:1998;262-268.
24. Portilla A. G., Sugarbaker P. H., Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 23:1999;23-29.
25. Loggie B. W., Fleming R. A., Geisinger K. R. Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Acta Cytol. 40:1996;1154-1158.
26. Cintron J. R., Pearl R. K. Colorectal cancer and peritoneal carcinomatosis. [review] [17 refs]. Semin Surg Oncol. 12:1996;267-278.
27. Hill A. D., Tran K. N., Akhurst T. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 229:1999;528-535.
28. Bilchik A. J., Giuliano A., Essner R. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am. 4:1998;351-358.
29. Gershenwald J. E., Thompson W., Mansfield P. F. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage i or ii melanoma patients. J Clin Oncol. 17:1999;976-983.
30. Nieweg O. E., Jansen L., Valdes Olmos R. A. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. European Journal of Nuclear Medicine. 26:1999;S11-6.
31. Bremers A. J., Kuppen P. J., Parmiani G. Tumour Immunotherapy: the adjuvant treatment of the 21st century? [In Press] Eur J Surg Oncol. 2000.
32. Roth J. A., Cristiano R. J. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 89:1997;21-39.
33. van der Eb M. M., Hoeben R. C., van de Velde C. J. Towards gene therapy for colorectal liver metastases. Rec Res Cancer Res. 147:1998;173-186.
34. Hollingsworth S. J., Barker S. G. E. Gene therapy: into the future of surgery. Lancet. 353:1999;SI 19-S120.
35. Ursin G., Bernstein L., Pike M. C. Breast cancer. Cancer Surv. 19/20:1994;241-264.
36. Nystrom L., Rutqvist L. E., Wall S. Breast cancer screening with mammography: overview of swedish randomised trials. Lancet. 341:1993;973-978.
37. Wright C. J., Mueller C. B. Screening mammography and public health policy: the need for perspective. Lancet. 346:1995;29-32.
38. de Koning H. J., Boer R., Warmerdam P. G., Beemsterboer P. M., van der Maas P. J. Quantitative interpretation of age-specific mortality reductions from the swedish breast cancer-screening trials. J Natl Cancer Inst. 87:1995;1217-1223.
39. de Koning H. J., Fracheboud J., Boer R. Nation-wide breast cancer screening in the netherlands: support for breast-cancer mortality reduction. national evaluation team for breast cancer screening. Int J Cancer. 60:1995;777-780.
40. Dixon J. M., Ravisekar O., Cunningham M., Anderson E. D., Anderson T. J., Brown H. K. Factors affecting outcome of patients with impalpable breast cancer detected by breast screening. Br J Surg. 1999;997-1001.
41. Blichert-Toft M. The axilla: to clear or not to clear? That is the question. Rec Res Cancer Res. 152:1998;149-160.
42. Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. Journal of Surgical Oncology. 66:1997;7-10.
43. Epstein R. J. Routine or delayed axillary dissection for primary breast cancer? Eur J Cancer. 31A:1995;1570-1573.
44. O'Higgins N., Linos D. A., Blichert-Toft M. European guidelines for quality assurance in the surgical management of mammographically detected lesions. Eur J Surg Oncol. 24:1998;96-98.
45. Woodcock N. P., Glaves I., Morgan D. R., MacFie J. Ultrasound-guided tru-cut biopsy of the breast. Ann R Coll Surg Engl. 80:1998;253-256.
46. Phillips G., McGuire L., Clowes D. The value of ultrasound-guided fine needle aspiration in the assessment of solid breast lumps. Australas Radiol. 38:1994;187-192.
47. Bonnema J., van Geel A. N., van Ooijen B. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. -. World J Surg. 21(3):1997;270-274.
48. Boetes C., Strijk S. P., Holland R., Barentsz J. O., Van Der Sluis R. F., Ruijs J. H. False-negative MR imaging of malignant breast tumors. Eur Radiol. 7(8):1997;1231-1234.
49. Friedrich M. MRI of the breast: state of the art. Eur Radiol. 8:1998;707-725.
50. Kramer S., Schulz-Wendtland R., Hagedorn K., Bautz W., Lang N. Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res. 18:1998;2159-2161.
51. Harms S. E. Breast magnetic resonance imaging. Semin Ultrasound CT MR. 19:1998;104-120.
52. Heywang-Kobrunner S. H., Viehweg P., Heinig A. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol. 24:1997;94-108.
53. Taillefer R. The role of 99mtc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med. 29:1999;16-40.
54. Veronesi U., Saccozzi R., Del Vecchio M. Comparing radical mastectomy with quandrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. New Eng J Med. 305:1981;6-11.
55. Veronesi U., Luini A., Galimberti V. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute Trials. World Journal of Surgery. 18:1994;70-75.
56. Fisher B., Redmond C., Poisson R. Eight year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. New Eng J Med. 320:1989;822-828.
57. Jacobson J. A., Danforth D. N., Cowan K. H. Ten-year results of a comparison of conservation with mastectomyin the treatment of stage I and II breast cancer. New Eng J Med. 332:1995;907-911.
58. Arriagada R., Le M. G., Rochard F. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data. J Clin Oncol. 14:1996;1558-1564.
59. van Dongen J. A., Bartelink H., Fentiman I. S. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial. J Natl Cancer Inst. 11:1992;15-18.
60. Blichert-Toft M., Rose C., Andersen J. A. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. J Natl Cancer Inst Monogr. 11:1992;19-25.
61. Liljegren G., Lindgren A., Bergh J., Nordgren H., Tabar L., Holmberg L. Risk factors for local recurrence after conservative treatment in stage i breast cancer. definition of a subgroup not requiring radiotherapy. Ann Oncol. 8:1997;235-241.
62. Salvadori B. Local recurrences after breast-conserving treatment: an open problem. Semin Surg Oncol. 12:1996;46-52.
63. Mauriac L., MacGrogan G., Avril A. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow-up. Annals of Oncology. 10:1999;47-52.
64. Kuerer H. M., Newman L. A., Smith T. L. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. J Clin Oncol. 17:1999;460-469.
65. Zurrida S., Greco M., Veronesi U. Surgical pitfalls after preoperative chemotherapy in large size breast cancer. Eur J Surg Oncol. 20:1994;641-643.
66. Veronesi U., Bonadonna G., Zurrida S. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 222:1995;612-618.
67. Honkoop A. H., Wagstaff J., Pinedo H. M. Management of stage iii breast cancer. Oncology. 55:1998;218-227.
68. Bates T., Riley D. L., Houghton J., Fallowfield L., Baum M. Breast cancer in elderly women: a cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. the elderly breast cancer working party. Br J Surg. 78:1991;591-594.
69. Richards M. A., Smith P., Ramirez A. J., Fentiman I. S., Rubens R. D. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 79:1999;858-864.
70. Fisher E. R., Sass R., Fisher B. Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no.4). x. discriminants for tenth year treatment failure. Cancer. 53:1984;: 712-23.
71. Carter C. L., Allen C., Henson D. E. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 63:1989;181-187.
72. JAMA. 265:1991;391-395.
73. Lancet. 352:1998;930-942.
74. Overgaard M. Postoperative radiotherapy in high-risk premenopauzal women with breast cancer who receive adjuvant chemotherapy. New Eng J Med. 337:1997;949-955.
75. Keramopoulos A., Tsionou C., Minaretzis D., Michalas S., Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology. 50:1993;445-449.
76. Ivens D., Hoe A. L., Podd T. J., Hamilton C. R., Taylor I., Royle G. T. Assessment of morbidity from complete axillary dissection. Br J Cancer. 66:1992;136-138.
77. Kissin M. W., Querci della Rovere G., Easton D., Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg. 73:1986;580-584.
78. Rutgers E. J., Peterse H. L. Future prospects for the staging of breast cancer. Semin Surg Oncol. 12:1996;3-11.
79. Hsueh E. C. J Amer Coll Surg. 189:1999;207-213.
80. Nieweg O. E., Rutgers E. J. World Journal of Surgery. 1999.
81. Cabanas R. M. An approach for the treatment of penile carcinoma. Cancer. 39:1977;456-466.
82. Morton D. L., Wen D. R., Wong J. H. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 127:1992;392-399.
83. Cancer. 80:1997;1798-1802.
84. Gupta S. K., Douglas-Jones A. G., Fenn N., Morgan J. M., Mansel R. E. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer. 80:1997;1740-1745.
85. Holland R., Hendriks J. H., Vebeek A. L., Mravunac M., Schuurmans Stekhoven J. H. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 335:1990;519-522.
86. Silverstein M. J., Lagios M. D., Groshen S. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 340:1999;1455-1461.
87. Fisher E. R., Costantino J., Fisher B., Palekar A. S., Redmond C., Mamounas E. Pathologic findings from the national surgical adjuvant breast project (nsabp) protocol b-17. intraductal carcinoma (ductal carcinoma in situ). the national surgical adjuvant breast and bowel project collaborating investigators. Cancer. 75:1995;1310-1319.
88. Fentiman I. S. Trials of treatment for non-invasive breast cancer. Recent Results Cancer Res. 152:1998;135-142.
89. Fisher B., Dignam J., Wolmark N. Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project b-24 randomised controlled trial. Lancet. 353:1999;1993-2000.
90. Ford D., Easton D. F., Stratton M. Genetic heterogeneity and penetrance analysis of the brca1 and brca2 genes in breast cancer families. the breast cancer linkage consortium. Am J Hum Genet. 62:1998;676-689.
91. Stefanek M. E. Bilateral prophylactic mastectomy: issues and concerns. J Natl Cancer Inst Monogr. 1995;37-42.
92. Mann G. B., Borgen P. I. Breast cancer genes and the surgeon. J Surg Oncol. 67:1998;267-274.
93. Kennedy E. P., Hamilton S. R. Genetics of colorectal cancer. Semin Surg Oncol. 15:1998;126-130.
94. Herfarth C., Heuschen G., Heuschen U. A. [Malignant transformation in ulcerative colitis and surgical implications]. Chirurg. 69:1998;1020-1027.
95. Moynihan B. G. The surgical treatment of cancer of the sigmoid flexure and rectum: with special attention to the principles observed. Surg Gynec Obs. 6:1908;463-466.
96. Miles W. E. A method of performing abdomino-perineal resection for carcinoma of the rectum and of the terminal portion of the pelvic colon. Lancet. 11:1908;1812-1813.
97. Miles, W. E. AnonymousLettsomiam Lectures. Cancer of the Rectum, London, Harrison and Sons, 1923.
98. Best R. R., Blair J. B. Sphincter preserving operations for rectal carcinoma as related to the anatomy of the lymphatics. Ann Surg. 130:1949;538-576.
99. Grinnell R. S. Distal intramural spread of carcinoma of the rectum and rectosigmoid. Surg Gynec Obs. 99:1954;421-430.
100. Williams N. S., Dixon M. F., Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients' survival. Brit J Surg. 70:1983;150-154.
101. Andreola S., Leo E., Belli F. Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Dis Colon Rectum. 40:1997;25-29.
102. Heald R. J., Husband E. M., Ryall R. D. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Brit J Surg. 69:1982;613-616.
103. Heald R. J. Rectal Cancer: the surgical options. Eur J Cancer. 31A:1995;1189-1192.
104. Lloyd-Davies O. V. Radical excision of carcinoma of the rectum with conservation of the sphincters. Proc Natl Acad Sci USA. 41:1948;822-826.
105. Karanjia N. D., Corder A. P., Bearn P., Heald R. J. Leakage from stapled low anastomosis after total mesorectal excision for carcinoma of the rectum. Brit J Surg. 81:1994;1224-1226.
106. Heald, R. J.Soreide, O.Norstein, J. Rectal Cancer Surgery. Berlin/Heidelberg, Springer, 1997, 15, Total Mesorectal Excision: History and Anatomy of an Operation, 203, 19.
107. McCall J. L., Cox M. R., Wattchow D. A. Analysis of local recurrence rates after surgery alone for rectal cancer. Int J Colorectal Dis. 10:1995;126-132.
108. Dahlberg M., Glimelius B., Pahlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of swedish rectal cancer trial. Ann Surg. 229:1999;493-497.
109. Turnbull R. B., Kyle K., Watson F. R. Cancer of the colon; the influence of the no-touch isolation technique on survival rates. Ann Surg. 18:1968;82-88.
110. Wiggers T., Jeekel J., Arends J. W. The no-touch isolation technique in colon cancer: a prospective controlled multicentre trial. Brit J Surg. 75:1985;409-415.
111. Michelassi F., Vannuci L., Alaya J. A., Chappel R., Goldberg R., Block G. E. Local recurrence after curative resection of colorectal carcinoma. Surgery. 108:1990;787-792.
112. Schlag P. M., Benhidjeb T., Kilpert B. [Principles of curative resection of liver metastases]. Chirurg. 70:1999;123-132.
113. Yamamoto J., Shimada K., Kosuge T., Yamasaki S., Sakamoto M., Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Brit J Surg. 86:1999;332-337.
114. Chen H. S., Gross J. F. Intra-arterial infusion of anticancer drug: theoretic aspects of drug delivery and review of responses. Cancer treatment rep. 64:1980;31-40.
115. Laufman L., Nims T., Guy J. T., Guy J. F., Courter S. Hepatic arterial ligation and portal vein infusion for liver metastases from colorectal cancer. J Clin Oncol. 2:1984;1382-1389.
116. van de Velde, C. J.Tjaden, U. R.Kothuis, B. J.L.van de Velde, C. J.Sugarbaker, P. Liver metastases. Isolated regional liver perfusion in the treatment of hepatic metastases. Amsterdam, Nijhoff, 1984.
117. Kuppen P. J., Jonges L. E., van de Velde C. J. Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Brit J Cancer. 75:1997;1497-1500.
118. Marinelli A., de Brauw L. M., Beerman H. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jap J Clin Onc. 26:1996;341-350.
119. JAMA. 264:1990;1444-1450.
120. Moertel C. G., Fleming T. R., MacDonald J. S. Levamisole and fluorouracil for adjuvant therapy of resectedcolon carcinoma. New Eng J Med. 322:1990;352-356.
121. Stamos M. J. Colon and Rectal Surgery. J Amer Coll Surg. 186:1998;134-140.
122. Bremers A. J., Parmiani G. Immunotherapy for colon cancer. Lancet. 353:1999;1524-1525.
123. Vermorken J. B., Claessen A. M., van Tinteren H. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 353:1999;345-350.
124. Hoover H. C. Jr, Brandhorst J. S., Peters L. C. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 11:1993;390-399.
125. Schlag P., Manasterski M., Gerneth T. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother. 35:1992;325-330.
126. Riethmueller G., Holz E., Schlimok G. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 16:1998;1788-1794.
127. Macintyre I. M., Akoh J. A. Improving survival in gastric cancer: review of operative mortality in English language publications from 1970. Brit J Surg. 78:1991;771-776.
128. Akoh J. A., Macintyre I. M. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Brit J Surg. 79:1992;293-299.
129. Woelfler A. Ueber die Herrn Professor Billroth ausgefuehrten Resectionen des carcinomatoesen Pylorus. Anonymous. 1881.
130. Mikulicz J. Beitrage zur Technik der Operation des Magencarcinoms. Arch Klin Chir Berl. 1:1898;524-532.
131. Cunéo D. De l'envahissement du système lymphatique dans le cancer de l'estomac et de ses consequences chirurgicales. Anonymous. 1900.
132. Jamieson J. K., Dobson J. F. The lymphatic system of the stomach. Lancet. 1907;1061-1066.
133. Pack G. T., McNeer G. P. Total gastrectomy for cancer: a collective review of the literature and an original repor on 20 cases. Internat Abstr Surg. 77:1943;265-299.
134. Eker R. Carcinoma of the stomach. Investigation of the lymphatic spread from gastric carcinomas after total and partial gastrectomy. Act Chir Scand. 101:1951;112-126.
135. Kampschoer G. H., Fujii A., Masuda Y. Gastric cancer detected by mass survey. Comparison between mass survey and outpatient detection. Scandinavian Journal of Gastroenterology. 24:1989;813-817.
136. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Japanese Journal of Surgery. 11:1981;127-139.
137. Kinoshita, T. Maruyama, K. Sasako, M. Nishi, M.Ichakawa, H.Nakajima, T.Maruyama, K.Tahara, E. Gastric cancer. Treatment results of gastric cancer patients: Japanese experience, Tokyo/Berlin/Heidelberg, Springer Verlag, 1993.
138. Wanebo H. J., Kennedy B. J., Chmiel J., Steele G. Jr, Winchester D., Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 218:1993;583-592.
139. Maruyama K., Gunven P., Okabayashi K., Sasako M., Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg. 210:1989;596-602.
140. Cuschieri A. Recent advances in gastrointestinal malignancy. Ann Chir Gynaec. 78:1989;228-237.
141. Bonenkamp J. J., van de Velde C. J., Kampschoer G. H. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World Journal of Surgery. 17:1993;410-4; discussion 415.
142. Bonenkamp J. J., Hermans J., Sasako M., van de Velde C. J. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. New Eng J Med. 340:1999;908-914.
143. Dent D. M., Madden M. V., Price S. K. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Brit J Surg. 75:1988;110-112.
144. Robertson C. S., Chung S. C., Woods S. D. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg. 220:1994;176-182.
145. Bonenkamp J. J., Songun I., Hermans J. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 345:1995;745-748.
146. Cuschieri A., Fayers P., Fielding J. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 347:1996;995-999.
147. Cuschieri A., Weeden S., Fielding J. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Brit J Cancer. 79:1999;1522-1530.
148. Viste A., Haugstvedt T., Eide G. E., Soreide O. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg. 207:1988;7-13.
149. Bottcher K., Siewert J. R., Roder J. D., Busch R., Hermanek P., Meyer H. J. [Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (′92)]. Chirurg. 65:1994;298-306.
150. Gennari L., Bozzetti F., Bonfanti G. Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: a new approach to an old problem. Brit J Surg. 73:1986;534-538.
151. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Brit J Surg. 84:1997;1567-1571.
152. Bozzetti F., Marubini E., Bonfanti G. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 226:1997;613-620.
153. Kodera Y., Yamamura Y., Shimizu Y. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World Journal of Surgery. 21:1997;622-7; discussion 627-8.
154. Kitamura K., Nishida S., Ichikawa D. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Brit J Surg. 86:1999;119-122.
155. Viste A., Svanes K., Janssen C. W. Jr, Maartmann-Moe H., Soreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. European Journal of Surgery. 160:1994;497-502.
156. Griffith J. P., Sue-Ling H. M., Martin I. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 36:1995;684-690.
157. Arak A., Kull K. Factors influencing survival of patients after radical surgery for gastric cancer. A regional study of 406 patients over a 10-year period. Acta Oncologica. 33:1994;913-920.
158. Lisborg P., Jatzko G., Horn M. Radical surgery (R2 resection) for gastric cancer. A multivariate analysis. Scandinavian Journal of Gastroenterology. 29:1994;1024-1028.
159. Roukos D. H., Lorenz M., Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 123:1998;573-578.
160. Degiuli M., Sasako M., Ponzetto A. Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol. 23:1997;310-314.
161. Brady M. S., Rogatko A., Dent L. L., Shiu M. H. Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Archives of Surgery. 126:1991;359-364.
162. Aldridge M. C., Williamson R. C. Distal pancreatectomy with and without splenectomy. Brit J Surg. 78:1991;976-979.
163. Kaneda M., Horimi T., Ninomiya M. Adverse affect of blood transfusions on survival of patients with gastric cancer. Transfusion. 27:1987;375-377.
164. Sugezawa A., Kaibara N., Sumi K. Blood transfusion and the prognosis of patients with gastric cancer. Journal of Surgical Oncology. 42:1989;113-116.
165. Sasako M., McCulloch P., Kinoshita T., Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Brit J Surg. 82:1995;346-351.
166. Bollschweiler E., Boettcher K., Hoelscher A. H. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Brit J Surg. 79:1992;156-160.
167. Boku T., Nakane Y., Minoura T. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Brit J Surg. 77:1990;436-439.
168. Nakajima T., Harashima S., Hirata M., Kajitani T. Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytologica. 22:1978;225-229.
169. Bonenkamp J. J., Songun I., Hermans J., van de Velde C. J. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Brit J Surg. 83:1996;672-674.
170. Damhuis R. A., Tilanus H. W. The influence of age on resection rates and postoperative mortality in 2773 patients with gastric cancer. Eur J Cancer. 31A:1995;928-931.
171. Kranenbarg E. K., van de Velde C. J. Gastric cancer in the elderly. Eur J Surg Oncol. 24:1998;384-390.
172. McCulloch P. D1 versus D2 dissection for gastric cancer. Lancet. 345:1995;1516-7; discussion 1517-8.
173. Parikh D., Johnson M., Chagla L., Lowe D., McCulloch P. D2 gastrectomy: lessons from a prospective audit of the learning curve. Brit J Surg. 83:1996;1595-1599.
174. McCulloch P. Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980-1985. Brit J Surg. 81:1994;417-420.
175. Bonenkamp J. J., van de Velde C. J., Sasako M., Hermans J. R2 compared with R1 resection for gastric cancer: morbidity and mortality in a prospective, randomised trial. European Journal of Surgery. 158:1992;413-418.
176. Bozzetti F., Bonfanti G., Audisio R. A. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynec Obs. 164:1987;151-154.
177. Haugstvedt T., Viste A., Eide G. E., Soreide O. The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. Norwegian Stomach Cancer Trial. World Journal of Surgery. 13:1989;617-21; discussion 621-2.
178. Meijer S., De Bakker O. J., Hoitsma H. F. Palliative resection in gastric cancer. Journal of Surgical Oncology. 23:1983;77-80.
179. Monson J. R., Donohue J. H., McIlrath D. C., Farnell M. B., Ilstrup D. M. Total gastrectomy for advanced cancer. A worthwhile palliative procedure. Cancer. 68:1991;1863-1868.
180. MacDonald J. S., Woolley P. V., Smythe T., Ueno W., Hoth D., Schein P. S. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 44:1979;42-47.
181. Hermans J., Bonenkamp J. J., Boon M. C. Author update of adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. [In Press] J Clin Oncol. 1999.
182. Hermans J., Bonenkamp J. J., Boon M. C. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 11:1993;1441-1447.
183. Ellis, P.Cunningham D; Sigamura, T.Sasako, M. Gastric Cancer. Adjuvant and neoadjuvant chemotherapy, Oxford/New York/Tokyo, Oxford University Press, 1997.
184. Takahashi K., Harauchi D., Kimura S., Saito S., Monden Y. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Int J Immunopharm. 20:1998;375-388.
185. Kim J. P., Kwon O. J., Oh S. T., Yang H. K. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg. 216:1992;269-78; discussion 278-9.
186. Norris W. Case of fungoid disease. Edinburgh Medical and Surgical Journal. 16:1820;562.
187. Coats J. On a case of multiple melanotic sarcoma. Glasgow Medical Journal. 24:1885;92.
188. Handley W. S. The pathology of melanotic growths in relation to their operative treatment. Lancet. 927:1907;99.
189. Clark, W. H. London, Pergamom, 1967, A classification of malignant melanoma in man correlated with histogenesis and biological behavior. 621, 45.
190. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 172:1970;902-908.
191. Veronesi U., Cascinelli N., Adamus J. Narrow excision (1 cm margin): a safe procedure for thin cutaneous melanoma. Results of an international randomizedtrial. Archives of Surgery. 126:1991;438-441.
192. Balch C. M., Urist M. M., Karakousis C. P. Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 218:1993;262-267.
193. Jonk A., Kroon B. B., Rumke P., van der Esch E. P., Hart A. A. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator lymph nodes, or both. Surg Gynec Obs. 167:1988;28-32.
194. Karakousis C. P., Emrich L. J., Driscoll D. L., Rao U. Survival after groin dissection for malignant melanoma. Surgery. 109:1991;119-126.
195. Coit D. G., Brennan M. F. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Archives of Surgery. 124:1989;162-166.
196. Eve F. A lecture on melanoma. Practitioner. 70:1903;165.
197. Veronesi U., Adamus J., Bandiera D. C. Inefficacy of immediate node dissection in stage I melanoma of the limbs. New Eng J Med. 297:1977;627.
198. Sim F. H., Taylor W. F., Pritchard D. J., Soule E. H. Lymphadenectomy in the management of stage i malignant melanoma: a prospective randomized study. Mayo Clin Proc. 61:1986;697-705.
199. Balch C. M., Soong S. J., Bartolucci A. A. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 224:1996;255-263.
200. Morton D. L. Sentinel lymphadenectomy for patients with clinical stage i melanoma. J Surg Oncol. 66:1997;267-269.
201. Stehlin J. S. Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynec Obs. 129:1969;305-308.
202. Thompson J. F., Hunt J. A., Shannon K. F., Kam P. C. Frequency and duration of remission after isolated limb perfusion for melanoma. Archives of Surgery. 132:1997;903-907.
203. Taber S. W., Polk H. C. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol. 4:1997;440-445.
204. Koops H. S., Vaglini M., Suciu S. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 16:1998;2906-2912.
205. Manusama E. R., Nooijen P. T., Ten Hagen T. L. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program. Sem Surg Oncol. 14:1998;232-237.
206. Lienard D., Eggermont A. M., Kroon B. B., Schraffordt Koops H., Lejeune F. J. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Sem Surg Oncol. 14:1998;202-209.
207. Agarwala S. S., Kirkwood J. M. Adjuvant interferon treatment for melanoma. Hematology - Oncology Clinics of North America. 12:1998;823-833.
208. Pehamberger H., Soyer H. P., Steiner A. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 16:1998;1425-1429.
209. Grob J. J., Dreno B., de la Salmoniere P. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 351:1998;1905-1910.
210. Eggermont A. M. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs. Melanoma Res. 7 Suppl 2:1997;S127-31.
211. Elias E. G., Suter C. M., Fabian D. S. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. Journal of Surgical Oncology. 64:1997;17-22.
212. Rosenberg S. A., Yannelli J. R., Yang J. C. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 86:1994;1159-1166.